Clinical effects of dexamethasone among patients with sickle cell disease hospitalized with COVID-19: Outcomes from a single academic health system
We analyzed outcomes among patients with SCD who were hospitalized for COVID-19 and eligible for dexamethasone. Our study suggests that in this population, treatment with dexamethasone increases the risk of incident VTE. There was a suggestion of an increased risk of ICU admission as well as increased length of hospitalization; larger studies are needed to confirm these findings.
Authors
- Catherine R. Lesko (ORCID: https://orcid.org/0000-0002-1717-2592)
- Matthew Lankiewicz
- Kelly A. Gebo (ORCID: https://orcid.org/0000-0003-4010-398X)
- Ashley Lauriello
- Sophie Lanzkron (ORCID: https://orcid.org/0000-0002-2878-0251)
- William M. Garneau (ORCID: https://orcid.org/0000-0002-1849-1640)
Institutions
- Johns Hopkins University (US)
- Thomas Jefferson University (US)
- Johns Hopkins Bayview Medical Center (US)
- Johns Hopkins Hospital (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1371/journal.pone.0313289
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Johns Hopkins University
- CSL Behring
- National Institutes of Health
- National Center for Advancing Translational Sciences